首页> 外文期刊>Analytica chimica acta >The application of high-resolution mass spectrometry-based data-mining tools in tandem to metabolite profiling of a triple drug combination in humans
【24h】

The application of high-resolution mass spectrometry-based data-mining tools in tandem to metabolite profiling of a triple drug combination in humans

机译:基于高分辨率质谱的数据挖掘工具在人类三联药物组合的代谢产物分析中的应用

获取原文
获取原文并翻译 | 示例
           

摘要

Patients are usually exposed to multiple drugs, and metabolite profiling of each drug in complex biological matrices is a big challenge. This study presented a new application of an improved high resolution mass spectrometry (HRMS)-based data-mining tools in tandem to fast and comprehensive metabolite identification of combination drugs in human. The model drug combination was metronidazole-pantoprazole-clarithromycin (MET-PAN-CLAR), which is widely used in clinic to treat ulcers caused by Helicobacter pylori. First, mass defect filter (MDF), as a targeted data processing tool, was able to recover all relevant metabolites of MET-PAN-CLAR in human plasma and urine from the full-scan MS dataset when appropriate MDF templates for each drug were defined. Second, the accurate mass-based background subtraction (BS), as an untargeted data-mining tool, worked effectively except for several trace metabolites, which were buried in the remaining background signals. Third, an integrated strategy, i.e., untargeted BS followed by improved MDF, was effective for metabolite identification of MET-PAN-CLAR. Most metabolites except for trace ones were found in the first step of BS-processed datasets, and the results led to the setup of appropriate metabolite MDF template for the subsequent MDF data processing. Trace metabolites were further recovered by MDF, which used both common MDF templates and the novel metabolite-based MDF templates. As a result, a total of 44 metabolites or related components were found for MET-PAN-CLAR in human plasma and urine using the integrated strategy. New metabolic pathways such as N-glucuronidation of PAN and dehydrogenation of CLAR were found. This study demonstrated that the combination of accurate mass-based multiple data-mining techniques in tandem, i.e., untargeted background subtraction followed by targeted mass defect filtering, can be a valuable tool for rapid metabolite profiling of combination drugs in vivo. (C) 2015 Elsevier B.V. All rights reserved.
机译:患者通常会接触多种药物,在复杂的生物基质中每种药物的代谢物谱分析是一个巨大的挑战。这项研究提出了基于改进的高分辨率质谱法(HRMS)的数据挖掘工具的新应用,以快速,全面地鉴定人体内联合药物的代谢物。模型药物组合为甲硝唑-top托拉唑-克拉霉素(MET-PAN-CLAR),在临床上广泛用于治疗由幽门螺杆菌引起的溃疡。首先,当定义了每种药物的适当MDF模板时,质量缺陷过滤器(MDF)作为目标数据处理工具,能够从全扫描MS数据集中回收人血浆和尿液中所有相关的MET-PAN-CLAR代谢物。 。其次,精确的基于质量的背景减法(BS)作为一种无目标的数据挖掘工具,除了掩盖在其余背景信号中的几种痕量代谢物外,都能有效发挥作用。第三,一种综合策略,即无针对性的BS继之以改良的MDF,对于识别MET-PAN-CLAR的代谢物是有效的。在BS处理的数据集的第一步中发现了除痕量代谢物外的大多数代谢物,结果导致为后续MDF数据处理建立了合适的代谢物MDF模板。微量代谢物通过MDF进一步回收,MDF同时使用了常见的MDF模板和新型的基于代谢物的MDF模板。结果,使用该综合策略,在人血浆和尿液中共发现MET-PAN-CLAR的44种代谢物或相关成分。发现了新的代谢途径,例如PAN的N-葡糖醛酸化和CLAR的脱氢。这项研究表明,将精确的基于质量的多种数据挖掘技术相结合的方法,即无目标背景扣除后再进行有针对性的质量缺陷过滤,可以成为体内组合药物快速代谢物谱分析的有价值的工具。 (C)2015 Elsevier B.V.保留所有权利。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号